Statistics

Total Visits

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)19

Select a period of time:

Number of views in the range

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)5

Views

Views
August 20241
September 20240
October 20240
November 20243
December 20240
January 20251
February 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Belgium1
Spain1
United Kingdom1
Mexico1
United States1
 

Top cities views

Views
Chicago1
Santiago de Compostela1